Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 309


Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis.

Simon GR, Schell MJ, Begum M, Kim J, Chiappori A, Haura E, Antonia S, Bepler G.

Cancer. 2012 May 1;118(9):2525-31. doi: 10.1002/cncr.26522. Epub 2011 Oct 25.


RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.

Zhang GB, Chen J, Wang LR, Li J, Li MW, Xu N, Wang Y, Shentu JZ.

Cancer Chemother Pharmacol. 2012 May;69(5):1277-87. doi: 10.1007/s00280-012-1834-x.


Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.

Mazzoni F, Cecere FL, Meoni G, Giuliani C, Boni L, Camerini A, Lucchesi S, Martella F, Amoroso D, Lucherini E, Torricelli F, Di Costanzo F.

Lung Cancer. 2013 Nov;82(2):288-93. doi: 10.1016/j.lungcan.2013.08.018. Epub 2013 Sep 3.


Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.

Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haura E, Antonia S, Fischer JR.

J Clin Oncol. 2013 Jul 1;31(19):2404-12. doi: 10.1200/JCO.2012.46.9783. Epub 2013 May 20.


ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer.

Su C, Zhou S, Zhang L, Ren S, Xu J, Zhang J, Lv M, Zhang J, Zhou C.

Med Oncol. 2011 Dec;28(4):1411-7. doi: 10.1007/s12032-010-9553-9. Epub 2010 May 14.


Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer.

Reynolds C, Obasaju C, Schell MJ, Li X, Zheng Z, Boulware D, Caton JR, Demarco LC, O'Rourke MA, Shaw Wright G, Boehm KA, Asmar L, Bromund J, Peng G, Monberg MJ, Bepler G.

J Clin Oncol. 2009 Dec 1;27(34):5808-15. doi: 10.1200/JCO.2009.21.9766. Epub 2009 Nov 2.


ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.

Ceppi P, Volante M, Novello S, Rapa I, Danenberg KD, Danenberg PV, Cambieri A, Selvaggi G, Saviozzi S, Calogero R, Papotti M, Scagliotti GV.

Ann Oncol. 2006 Dec;17(12):1818-25. Epub 2006 Sep 15.


High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.

Ren S, Zhou S, Zhang L, Xu J, Lv M, Zhang J, Zhou C, Zhang J.

Cancer Invest. 2010 Dec;28(10):1078-83. doi: 10.3109/07357901003735659. Epub 2010 May 26.


Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.

Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C, Provencio M, Isla D, Taron M, Diz P, Artal A; Spanish Lung Cancer Group.

Clin Cancer Res. 2004 Feb 15;10(4):1318-25.


Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.

Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, Lopez-Vivanco G, Camps C, Botia M, Nuñez L, Sanchez-Ronco M, Sanchez JJ, Lopez-Brea M, Barneto I, Paredes A, Medina B, Artal A, Lianes P.

Ann Oncol. 2004 Aug;15(8):1194-203.


Influence of genetic markers on survival in non-small cell lung cancer.

Rosell R, Taron M, Camps C, López-Vivanco G.

Drugs Today (Barc). 2003 Oct;39(10):775-86. Review.


The tailored chemotherapy based on RRM1 immunohistochemical expression in patients with advanced non-small cell lung cancer.

Nie X, Cheng G, Ai B, Zhang S.

Cancer Biomark. 2013 Jan 1;13(6):433-40. doi: 10.3233/CBM-130381.


Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy.

Zhao H, Zhang H, Du Y, Gu X.

Tumour Biol. 2014 Dec;35(12):12679-88. doi: 10.1007/s13277-014-2592-7. Epub 2014 Sep 17.


Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.

Simon G, Sharma A, Li X, Hazelton T, Walsh F, Williams C, Chiappori A, Haura E, Tanvetyanon T, Antonia S, Cantor A, Bepler G.

J Clin Oncol. 2007 Jul 1;25(19):2741-6.


Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.

Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H.

Lung Cancer. 2009 Jun;64(3):326-33. doi: 10.1016/j.lungcan.2008.09.002. Epub 2008 Nov 1.


Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients.

Mlak R, Krawczyk P, Ramlau R, Kalinka-Warzocha E, Wasylecka-Morawiec M, Wojas-Krawczyk K, Kucharczyk T, Homa I, Kozioł P, Ciesielka M, Chudziak D, Milanowski J.

Oncol Rep. 2013 Nov;30(5):2385-98. doi: 10.3892/or.2013.2696. Epub 2013 Aug 26.


Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery.

Rosell R, Felip E, Taron M, Majo J, Mendez P, Sanchez-Ronco M, Queralt C, Sanchez JJ, Maestre J.

Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4215s-4219s.


RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy.

Dong S, Guo AL, Chen ZH, Wang Z, Zhang XC, Huang Y, Xie Z, Yan HH, Cheng H, Wu YL.

J Hematol Oncol. 2010 Mar 13;3:10. doi: 10.1186/1756-8722-3-10.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk